Founded in 2019, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address human genetic diseases (including many rare diseases) with high unmet needs.

A genetic disorder is an illness caused by changes (mutations) in a person’s DNA. There are over 6,000 genetic disorders, many of which are fatal or severely debilitating. Until now, many genetic diseases have no effective treatment, resulting in significantly unmet clinical needs. The completion of Human Genome Project in 2003 has helped to identify genes associated with many genetic diseases. As a result, scientists are able to develop diagnosis tools (there are over 2000 genetic tests available) and propose new, effective treatments. 

Our initial focus

Is to develop novel therapeutics for genetically associated kidney disorders, such as autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), Fabry disease (a disease wherein patients’ kidney functions are significantly compromised).

Our drug development approach

A lean execution team of dedicated, highly experienced industry professionals 

A large network of top-notch industry leaders, academic labs and CROs

A time- and capital-efficient platform to transform scientific discoveries into drug programs

© Copyright AceLink Therapeutics. All rights reserved